MCID: THY109
MIFTS: 56

Thyroid Cancer, Nonmedullary, 1

Categories: Genetic diseases, Rare diseases, Cancer diseases, Endocrine diseases

Aliases & Classifications for Thyroid Cancer, Nonmedullary, 1

MalaCards integrated aliases for Thyroid Cancer, Nonmedullary, 1:

Name: Thyroid Cancer, Nonmedullary, 1 57
Papillary Thyroid Carcinoma 12 53 29 6 15 73
Familial Nonmedullary Thyroid Cancer, Papillary 57 53 75
Nonmedullary Thyroid Carcinoma, Papillary 57 53 75
Non-Medullary Thyroid Carcinoma 75 73
Papillary Carcinoma of Thyroid 57 75
Thyroid Carcinoma, Papillary 76 13
Nmtc1 57 75
Pact 57 75
Papillary Carcinoma of Thyroid; Pact; Ptc; Tpc 57
Familial Nonmedullary Thyroid Gland Carcinoma 73
Papillary Carcinoma of the Thyroid Gland 12
Familial Non-Medullary Thyroid Cancer 75
Cancer, Thyroid, Nonmedullary, Type 1 40
Thyroid Carcinoma, Nonmedullary, 1 13
Thyroid Carcinoma, Nonmedullary 1 73
Thyroid Cancer, Non-Medullary, 1 75
Nonmedullary Thyroid Carcinoma 1 6
Nonmedullary Thyroid Carcinoma 75
Cancer, Thyroid, Nonmedullary 40
Thyroid Papillary Carcinoma 55
Thyroid Cancer, Papillary 44
Papillary Thyroid Cancer 55
Fnmtc 75
Nmtc 75
Ptc 75
Tpc 75

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
thyroid cancer, nonmedullary, 1:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 57 188550
Disease Ontology 12 DOID:3969
NCIt 50 C4035
SNOMED-CT 68 255029007 4797003
MedGen 42 C0238463
SNOMED-CT via HPO 69 263681008

Summaries for Thyroid Cancer, Nonmedullary, 1

OMIM : 57 Nonmedullary thyroid cancer (NMTC) comprises thyroid cancers of follicular cell origin and accounts for more than 95% of all thyroid cancer cases. The remaining cancers originate from parafollicular cells (medullary thyroid cancer, MTC; 155240). NMTC is classified into 4 groups: papillary, follicular (188470), Hurthle cell (607464), and anaplastic. Approximately 5% of NMTC is hereditary, occurring as a component of a familial cancer syndrome (e.g., familial adenomatous polyposis, 175100; Carney complex, 160980) or as a primary feature (familial NMTC or FNMTC). Papillary thyroid cancer (PTC) is the most common histologic subtype of FNMTC, accounting for approximately 85% of cases (summary by Vriens et al., 2009). PTC is characterized by distinctive nuclear alterations including pseudoinclusions, grooves, and chromatin clearing. PTCs smaller than 1 cm are referred to as papillary microcarcinomas. These tumors have been identified in up to 35% of individuals at autopsy, suggesting that they may be extremely common although rarely clinically relevant. PTC can also be multifocal but is typically slow-growing with a tendency to spread to lymph nodes and usually has an excellent prognosis (summary by Bonora et al., 2010). (188550)

MalaCards based summary : Thyroid Cancer, Nonmedullary, 1, also known as papillary thyroid carcinoma, is related to differentiated thyroid carcinoma and thyroid cancer. An important gene associated with Thyroid Cancer, Nonmedullary, 1 is NKX2-1 (NK2 Homeobox 1). The drugs Iodine and Salmon Calcitonin have been mentioned in the context of this disorder. Affiliated tissues include thyroid, lymph node and lung, and related phenotypes are papillary thyroid carcinoma and non-medullary thyroid carcinoma

Disease Ontology : 12 A thyroid carcinoma that is characterized by the small mushroom shape of the tumor which has a stem attached to the epithelial layer.

NIH Rare Diseases : 53 Papillary thyroid carcinoma is a form of cancer that occurs due to abnormal and uncontrolled cell growth of certain cells (follicular cells) of the thyroid. Many people with papillary thyroid carcinoma have no signs or symptoms of the condition. When present, symptoms may include a small lump at the base of the neck, hoarseness, difficulty swallowing, trouble breathing, and pain in the neck or throat. Although people of all ages may be diagnosed with the condition, women between ages 30 and 50 are most commonly affected. The cause of papillary thyroid carcinoma is currently unknown. Risks for developing thyroid cancer include a history of high-dose external radiation treatments to the neck and radiation exposure during nuclear plant disasters. The best treatment options depend on many factors, but may include surgery, radiation therapy (including radioactive iodine therapy), chemotherapy and thyroid hormone therapy.

UniProtKB/Swiss-Prot : 75 Thyroid cancer, non-medullary, 1: A form of non-medullary thyroid cancer (NMTC), a cancer characterized by tumors originating from the thyroid follicular cells. NMTCs represent approximately 95% of all cases of thyroid cancer and are classified into papillary, follicular, Hurthle cell, and anaplastic neoplasms.

Wikipedia : 76 Papillary thyroid cancer or papillary thyroid carcinoma is the most common type of thyroid cancer,... more...

Related Diseases for Thyroid Cancer, Nonmedullary, 1

Diseases in the Thyroid Cancer, Nonmedullary, 2 family:

Thyroid Cancer, Nonmedullary, 1 Thyroid Cancer, Nonmedullary, 3
Thyroid Cancer, Nonmedullary, 4 Thyroid Cancer, Nonmedullary, 5

Diseases related to Thyroid Cancer, Nonmedullary, 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 88)
# Related Disease Score Top Affiliating Genes
1 differentiated thyroid carcinoma 33.5 BRAF GAS8-AS1 NKX2-1
2 thyroid cancer 32.2 BRAF GAS5 H19 HOTAIR NKX2-1 PTCSC3
3 renal cell carcinoma, nonpapillary 31.3 CRNDE GAS5 H19 HOTAIR NKX2-1 PVT1
4 leukemia, chronic lymphocytic 31.0 BRAF CRNDE MIR146A MIR221
5 breast cancer 30.9 BRAF CRNDE GAS5 H19 HOTAIR MIR146A
6 multicentric papillary thyroid carcinoma 12.3
7 thyroid carcinoma, papillary, with papillary renal neoplasia 12.1
8 thyroid carcinoma, nonmedullary, with or without cell oxyphilia 11.9
9 multiple endocrine neoplasia, type iia 11.8
10 thyroid cancer, nonmedullary, 3 11.4
11 thiourea tasting 11.3
12 malignant pleural mesothelioma 11.2 GAS5 NKX2-1 PVT1
13 esophagus squamous cell carcinoma 11.2 BANCR HOTAIR
14 malignant glioma 11.2 CRNDE GAS5 H19
15 kidney cancer 11.2 GAS5 H19 HOTAIR PVT1
16 pancreatic ductal adenocarcinoma 11.2 H19 HOTAIR MIR221 PVT1
17 ovarian epithelial cancer 11.2 H19 HAGLR HOTAIR
18 oral squamous cell carcinoma 11.2 H19 HOTAIR MIR146A MIR221
19 osteogenic sarcoma 11.2 BANCR H19 HOTAIR PVT1
20 gastrointestinal system cancer 11.2 BANCR H19 HOTAIR
21 bladder urothelial carcinoma 11.2 BRAF CRNDE GAS5 HOTAIR PVT1
22 familial papillary or follicular thyroid carcinoma 11.2
23 adamantinoma of long bones 11.2 BRAF GAS5 H19 HOTAIR PVT1
24 squamous cell carcinoma, head and neck 11.2 BRAF GAS5 H19 HOTAIR MIR221
25 myeloma, multiple 11.2 BRAF GAS5 H19 HOTAIR PVT1
26 prostate disease 11.2 GAS5 H19
27 coronary artery anomaly 11.2 GAS5 H19 MIR221 MIR222
28 lung cancer susceptibility 3 11.2 BRAF GAS5 H19 HOTAIR NKX2-1
29 struma ovarii 11.1 BRAF NKX2-1
30 glioblastoma 11.1 BRAF GAS5 H19 HOTAIR MIR221 MIR222
31 gastric cardia adenocarcinoma 11.1 H19 HOTAIR
32 gastric adenocarcinoma 11.1 BANCR BRAF H19 HOTAIR
33 gallbladder cancer 11.1 CRNDE H19 HOTAIR
34 neuroblastoma 11.1 GAS5 H19 HAGLR HOTAIR MIR221
35 melanoma 11.1 BANCR BRAF GAS5 H19 HOTAIR MIR221
36 cervical cancer 11.1 CRNDE GAS5 H19 HAGLR HOTAIR PVT1
37 thyroid cancer, nonmedullary, 2 11.1
38 bladder cancer 11.1 BANCR GAS5 H19 HAGLR HOTAIR MIR221
39 nasopharyngeal carcinoma 11.1 GAS5 H19 HOTAIR PVT1
40 leukemia, acute myeloid 11.0 HOTAIR MIR146A MIR221 MIR222
41 dermatomyositis 11.0 MIR221 MIR222
42 pancreatic cancer 11.0 CRNDE GAS5 H19 HOTAIR MIR146A MIR221
43 astrocytoma 11.0 H19 HOTAIR PVT1
44 newborn respiratory distress syndrome 11.0 BRAF NKX2-1
45 ovarian cancer 11.0 BRAF CRNDE GAS5 H19 HAGLR HOTAIR
46 prostate cancer 11.0 GAS5 H19 HOTAIR MIR146A MIR221 MIR222
47 hepatocellular carcinoma 10.9 BANCR CRNDE GAS5 H19 HAGLR HOTAIR
48 gastric cancer 10.9 BANCR CRNDE GAS5 H19 HAGLR HAGLROS
49 glioma 10.9 BRAF CCND2-AS1 CRNDE GAS5 H19 HAGLR
50 lung cancer 10.9 BANCR BRAF GAS5 H19 HAGLR HOTAIR

Graphical network of the top 20 diseases related to Thyroid Cancer, Nonmedullary, 1:



Diseases related to Thyroid Cancer, Nonmedullary, 1

Symptoms & Phenotypes for Thyroid Cancer, Nonmedullary, 1

Symptoms via clinical synopsis from OMIM:

57
Neoplasia:
nonmedullary thyroid carcinoma (papillary)
goiter, multinodular


Clinical features from OMIM:

188550

Human phenotypes related to Thyroid Cancer, Nonmedullary, 1:

32
# Description HPO Frequency HPO Source Accession
1 papillary thyroid carcinoma 32 HP:0002895
2 non-medullary thyroid carcinoma 32 HP:0040198

Drugs & Therapeutics for Thyroid Cancer, Nonmedullary, 1

Drugs for Thyroid Cancer, Nonmedullary, 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 141)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iodine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 7553-56-2 807
2
Salmon Calcitonin Approved, Investigational Phase 3,Phase 2 47931-85-1 16129616
3
Calcitonin gene-related peptide Investigational Phase 3,Phase 2 83652-28-2
4 Anti-Infective Agents Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
5 Anti-Infective Agents, Local Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
6 Hormones Phase 3,Phase 2,Phase 1,Not Applicable
7 cadexomer iodine Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
8 Micronutrients Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
9 Trace Elements Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
10 Bone Density Conservation Agents Phase 3,Phase 2
11 calcitonin Phase 3,Phase 2
12 Hormone Antagonists Phase 3,Phase 2
13 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
14
Rosiglitazone Approved, Investigational Phase 2,Phase 1 122320-73-4 77999
15
Everolimus Approved Phase 2 159351-69-6 6442177
16
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
17
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
18
Indinavir Approved Phase 2 150378-17-9 5362440
19
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
20
Azacitidine Approved, Investigational Phase 2,Phase 1 320-67-2 9444
21
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
22
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
23
Bortezomib Approved, Investigational Phase 2,Phase 1 179324-69-7 387447 93860
24
Calcium Carbonate Approved, Investigational Phase 2 471-34-1
25
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
26
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
27
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
28
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
29
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
30
Gefitinib Approved, Investigational Phase 2,Not Applicable 184475-35-2 123631
31
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
32
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
33
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
34
Tamoxifen Approved Phase 2 10540-29-1 2733526
35
Dabrafenib Approved, Investigational Phase 2,Phase 1,Not Applicable 1195765-45-7 44462760 44516822
36
Crizotinib Approved Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
37
Lenvatinib Approved, Investigational Phase 2 417716-92-8
38
Pembrolizumab Approved Phase 2 1374853-91-4
39
Trametinib Approved Phase 2 871700-17-3 11707110
40
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
41
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
42
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
43
Nicotinamide Approved, Investigational, Nutraceutical Phase 2 98-92-0 936
44
Alfacalcidol Approved, Nutraceutical Phase 2 41294-56-8 5282181
45
Ergocalciferol Approved, Nutraceutical Phase 2 50-14-6 5280793
46
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2 1406-16-2
47
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
48
Maleic acid Experimental Phase 2,Phase 1 110-16-7 444266
49
Doxil Approved June 1999 Phase 2 31703
50
Cediranib Investigational Phase 1, Phase 2 288383-20-0 9933475

Interventional clinical trials:

(show top 50) (show all 111)
# Name Status NCT ID Phase Drugs
1 Decision Making on Radioactive Iodine Treatment for Papillary Thyroid Cancer Completed NCT01083550 Phase 2, Phase 3
2 Lateral Neck Sentinel Lymph Node Biopsy(LSLNB)in PTC Completed NCT01137097 Phase 2, Phase 3
3 Prophylactic Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma Completed NCT00795782 Phase 3
4 A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen. Completed NCT00295763 Phase 3 Thyrogen (thyrotropin alfa for injection)
5 Extent of Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma Recruiting NCT01149161 Phase 2, Phase 3
6 IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients Recruiting NCT01398085 Phase 2, Phase 3
7 Iodine I 131 With or Without Thyroid-Stimulating Hormone in Treating Patients Who Have Undergone Surgery for Thyroid Cancer Active, not recruiting NCT00415233 Phase 3
8 ESTIMation of the ABiLity of Prophylactic Central Compartment Neck Dissection to Modify Outcomes in Low-risk Differentiated Thyroid Cancer Not yet recruiting NCT03570021 Phase 3
9 Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer Unknown status NCT00098852 Phase 2 rosiglitazone maleate
10 Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer Unknown status NCT01118065 Phase 2 everolimus
11 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
12 Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine Completed NCT00559949 Phase 2 Selumetinib
13 Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131 Completed NCT00085293 Phase 2 Decitabine
14 A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation Completed NCT01286753 Phase 2 Vemurafenib
15 Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer Completed NCT01502410 Phase 2 sorafenib tosylate
16 Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Completed NCT00104871 Phase 2 Bortezomib
17 Prevention of Hypocalcemia in Patients Undergoing Total Thyroidectomy Plus Central Neck Dissection Completed NCT00630214 Phase 2
18 Sutent Adjunctive Treatment of Differentiated Thyroid Cancer Completed NCT00668811 Phase 2 SU011248, Sutent
19 A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... Completed NCT00923481 Phase 2 Fostamatinib disodium
20 A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers Completed NCT01524978 Phase 2 cetuximab;vemurafenib;vemurafenib
21 Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine Completed NCT00098813 Phase 2 romidepsin
22 Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer Completed NCT00118248 Phase 2 tanespimycin
23 Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Completed NCT00729157 Phase 2
24 Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer Completed NCT01811212 Phase 2 Cabozantinib S-malate
25 Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer Completed NCT00519896 Phase 2 sunitinib malate
26 Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer Completed NCT00134043 Phase 2 vorinostat
27 Thalidomide in Treating Patients With Thyroid Cancer Completed NCT00026533 Phase 2 thalidomide
28 Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer Completed NCT00061906 Phase 2 celecoxib
29 Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer Completed NCT01164176 Phase 2 everolimus
30 Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy Completed NCT00095836 Phase 2 Gefitinib
31 A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer Completed NCT00121628 Phase 2 AMG 706
32 Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors Completed NCT00019331 Phase 2 DetoxPC
33 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
34 Thyroid Gland Removal With or Without Central Lymph Node Dissection in Treating Patients With Node Negative Thyroid Cancer Recruiting NCT02138214 Phase 2
35 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Recruiting NCT02568267 Phase 2 Entrectinib
36 Lenvatinib and Pembrolizumab in DTC Recruiting NCT02973997 Phase 2 Lenvatinib
37 Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer Recruiting NCT02393690 Phase 2 Selumetinib
38 Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer Recruiting NCT02152995 Phase 2 Trametinib
39 Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in People With Low-risk Papillary Thyroid Cancer Active, not recruiting NCT02408887 Phase 2
40 Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer Active, not recruiting NCT01723202 Phase 2 dabrafenib;trametinib
41 Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer Active, not recruiting NCT01208051 Phase 1, Phase 2 Cediranib Maleate;Lenalidomide
42 Sunitinib in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery Active, not recruiting NCT00381641 Phase 2 Sunitinib Malate
43 Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer Active, not recruiting NCT01709292 Phase 2 Vemurafenib (All Groups);Vemurafenib (Post Surgery) - Group A + C
44 Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer Not yet recruiting NCT03506048 Phase 2 Lenvatinib
45 Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer Terminated NCT00095693 Phase 2 sorafenib tosylate
46 Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. Terminated NCT02012231 Phase 1, Phase 2 PLX8394
47 Radiofrequency Ablation in Treating Patients Who Are Undergoing Surgery for Thyroid Cancer Unknown status NCT00103155 Phase 1
48 A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors Completed NCT01100619 Phase 1 rosiglitazone;XL184
49 Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer Completed NCT00004062 Phase 1 azacitidine;liothyronine sodium
50 Study of XL281 in Adults With Solid Tumors Completed NCT00451880 Phase 1 XL281;famotidine

Search NIH Clinical Center for Thyroid Cancer, Nonmedullary, 1

Cochrane evidence based reviews: thyroid cancer, papillary

Genetic Tests for Thyroid Cancer, Nonmedullary, 1

Genetic tests related to Thyroid Cancer, Nonmedullary, 1:

# Genetic test Affiliating Genes
1 Papillary Thyroid Carcinoma 29 CCDC6 GOLGA5 NCOA4 NKX2-1 PCM1 PRKAR1A TRIM24 TRIM33

Anatomical Context for Thyroid Cancer, Nonmedullary, 1

MalaCards organs/tissues related to Thyroid Cancer, Nonmedullary, 1:

41
Thyroid, Lymph Node, Lung, Endothelial, Liver, Bone, Breast

Publications for Thyroid Cancer, Nonmedullary, 1

Articles related to Thyroid Cancer, Nonmedullary, 1:

(show top 50) (show all 1586)
# Title Authors Year
1
iTRAQ analysis of urinary proteins: Potential use of gelsolin and osteopontin to distinguish benign thyroid goiter from papillary thyroid carcinoma. ( 29355489 )
2018
2
Malignant pleural effusion from papillary thyroid carcinoma diagnosed by pleural effusion cytology: A case report. ( 28960907 )
2018
3
Downregulation of long noncoding RNA H19 contributes to the proliferation and migration of papillary thyroid carcinoma. ( 29287713 )
2018
4
Long Non-coding RNA Linc-ROR Is Upregulated in Papillary Thyroid Carcinoma. ( 29280051 )
2018
5
A rare case of ectopic papillary thyroid carcinoma transformed into squamous cell carcinoma. ( 29451347 )
2018
6
miR-199a-5p inhibits the progression of papillary thyroid carcinoma by targeting SNAI1. ( 29427661 )
2018
7
Follow-up of parenchymal changes in the thyroid gland with diffuse autoimmune thyroiditis in children prior to the development of papillary thyroid carcinoma. ( 29872995 )
2018
8
Differentiation of the Follicular Variant of Papillary Thyroid Carcinoma From Classic Papillary Thyroid Carcinoma: An Ultrasound Analysis and Complement to Fine-Needle Aspiration Cytology. ( 28880405 )
2018
9
Risk factors stratifying malignancy of nodules in contralateral thyroid lobe in patients with pre-operative ultrasound indicated unilateral papillary thyroid carcinoma: A retrospective analysis from single centre. ( 29083503 )
2018
10
The role of SMAD3 in the genetic predisposition to papillary thyroid carcinoma. ( 29300379 )
2018
11
USP33 is a Biomarker of Disease Recurrence in Papillary Thyroid Carcinoma. ( 29533940 )
2018
12
Preoperatively undiagnosed papillary thyroid carcinoma in patients thyroidectomized for benign multinodular goiter. ( 29641730 )
2018
13
Risk Factors for Central Neck Lymph Node Metastases in Micro- Versus Macro-A Clinically NodeA Negative Papillary Thyroid Carcinoma. ( 29238850 )
2018
14
Papillary thyroid carcinoma presenting as acute suppurative thyroiditis: A case report and review of the literature. ( 29447798 )
2018
15
Primary squamous cell carcinoma of the thyroid associated with papillary thyroid carcinoma and Hashimoto's thyroiditis. ( 29914738 )
2018
16
Hashimoto's thyroiditis, nodular goiter or follicular adenoma combined with papillary thyroid carcinoma play protective role in patients. ( 29788738 )
2018
17
Solute carrier family 35 member F2 is indispensable for papillary thyroid carcinoma progression through activation of transforming growth factor-I^ type I receptor/apoptosis signal-regulating kinase 1/mitogen-activated protein kinase signaling axis. ( 29274137 )
2018
18
LncRNA CCND2-AS1 promotes proliferation, migration, and invasion in papillary thyroid carcinoma. ( 29366479 )
2018
19
Differential roles of RET isoforms in medullary and papillary thyroid carcinomas. ( 27872141 )
2017
20
Overexpression of NOTCH-regulated Ankyrin Repeat Protein is associated with papillary thyroid carcinoma progression. ( 28207739 )
2017
21
Evaluation of platelet indices as a useful marker in papillary thyroid carcinoma. ( 28319410 )
2017
22
Influence of coexistent Hashimoto's thyroiditis on the extent of cervical lymph node dissection and prognosis in papillary thyroid carcinoma. ( 28906015 )
2017
23
Higher urinary bisphenol A concentration and excessive iodine intake are associated with nodular goiter and papillary thyroid carcinoma. ( 28684549 )
2017
24
Cooccurrence of Metastatic Papillary Thyroid Carcinoma and<i>Salmonella</i>Induced Neck Abscess in a Cervical Lymph Node. ( 28261270 )
2017
25
A comparative study of nuclear 8-hydroxyguanosine expression in Autoimmune Thyroid Diseases and Papillary Thyroid Carcinoma and its relationship with p53, Bcl-2 and Ki-67 cancer related proteins. ( 28187375 )
2017
26
Window Resection for Intraluminal Cricotracheal Invasion by Papillary Thyroid Carcinoma. ( 28243696 )
2017
27
Hobnail variant of papillary thyroid carcinoma: molecular profiling and comparison to classical papillary thyroid carcinoma, poorly differentiated thyroid carcinoma and anaplastic thyroid carcinoma. ( 28423545 )
2017
28
Vascular endothelial growth factor G+405C polymorphism may contribute to the risk of developing papillary thyroid carcinoma. ( 27925342 )
2017
29
LncRNA PTCSC3/miR-574-5p Governs Cell Proliferation and Migration of Papillary Thyroid Carcinoma via Wnt/I^-Catenin Signaling. ( 28513866 )
2017
30
Relationships of BRAF mutation and HMGB1 to papillary thyroid carcinoma. ( 28342873 )
2017
31
Correlation between BRAF <sup>V600E</sup> mutation and clinicopathological features in pediatric papillary thyroid carcinoma. ( 28646474 )
2017
32
BRAF(V600E) mutation contributes papillary thyroid carcinoma and Hashimoto thyroiditis with resistance to thyroid hormone: A case report and literature review. ( 28928829 )
2017
33
Plasma lncRNA GAS8-AS1 as a Potential Biomarker of Papillary Thyroid Carcinoma in Chinese Patients. ( 28781594 )
2017
34
Frequent BRAF <sup>V600E</sup> and Absence of TERT Promoter Mutations Characterize Sporadic Pediatric Papillary Thyroid Carcinomas in Japan. ( 28176151 )
2017
35
Synchronous parathyroid carcinoma and papillary thyroid carcinoma in a patient with long-standing schizophrenia. ( 29032667 )
2017
36
Expression of BMP-4 in papillary thyroid carcinoma and its correlation with tumor invasion and progression. ( 28214211 )
2017
37
RASSF10 is Epigenetically Inactivated and Suppresses Cell Proliferation and Induces Cell Apoptosis by Activating the p53 Signalling Pathway in Papillary Thyroid Carcinoma Cancer. ( 28268222 )
2017
38
NADPH Oxidase NOX4 Is a Critical Mediator of BRAF<sup>V600E</sup>-Induced Downregulation of the Sodium/Iodide Symporter in Papillary Thyroid Carcinomas. ( 27401113 )
2017
39
Surgical treatment of locally advanced papillary thyroid carcinoma after response to lenvatinib: A case report. ( 29055877 )
2017
40
Somatic mutation profiling of hobnail variant of papillary thyroid carcinoma. ( 28062544 )
2017
41
Clinical and Morphologic Features of ETV6-NTRK3 Translocated Papillary Thyroid Carcinoma in an Adult Population Without Radiation Exposure. ( 28125451 )
2017
42
Comparison of Ultrasound Features of Primary Metastatic Papillary Thyroid Carcinoma and Recurrent/Persistent Metastatic Cervical Lymph Nodes. ( 29125111 )
2017
43
Ultrasound variants of autoimmune thyroiditis in children and adolescents and their clinical implication in relation to papillary thyroid carcinoma development. ( 28866751 )
2017
44
HSP90 inhibitor NVP-AUY922 induces cell apoptosis by disruption of the survivin in papillary thyroid carcinoma cells. ( 28412368 )
2017
45
Clinicopathological significance of loss of p27kip1 expression in papillary thyroid carcinoma. ( 27834461 )
2017
46
Papillary thyroid carcinoma metastasizing to anaplastic meningioma: an unusual case of tumor-to-tumor metastasis. ( 28600666 )
2017
47
Skin metastasis on the neck: an unusual presentation of recurrence of papillary thyroid carcinoma. ( 29142854 )
2017
48
Investigating the mechanisms of papillary thyroid carcinoma using transcriptome analysis. ( 28849102 )
2017
49
[<i>RET</i>/<i>PTC</i>rearrangement affects multifocal formation of papillary thyroid carcinoma]. ( 28635216 )
2017
50
Influence of chronic lymphocytic thyroiditis on the risk of persistent and recurrent disease in patients with papillary thyroid carcinoma and elevated antithyroglobulin antibodies after initial therapy. ( 28625809 )
2017

Variations for Thyroid Cancer, Nonmedullary, 1

UniProtKB/Swiss-Prot genetic disease variations for Thyroid Cancer, Nonmedullary, 1:

75
# Symbol AA change Variation ID SNP ID
1 NKX2-1 p.Ala339Val VAR_075769 rs537209983

ClinVar genetic disease variations for Thyroid Cancer, Nonmedullary, 1:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 GRCh37 Chromosome 7, 140453136: 140453136
2 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 GRCh38 Chromosome 7, 140753336: 140753336
3 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 NCBI36 Chromosome 7, 140099605: 140099605
4 NKX2-1 NM_001079668.2(NKX2-1): c.1106C> T (p.Ala369Val) single nucleotide variant Likely benign rs537209983 GRCh37 Chromosome 14, 36986583: 36986583
5 NKX2-1 NM_001079668.2(NKX2-1): c.1106C> T (p.Ala369Val) single nucleotide variant Likely benign rs537209983 GRCh38 Chromosome 14, 36517378: 36517378
6 PCM1 NM_006197.3(PCM1): c.2935C> T (p.Gln979Ter) single nucleotide variant Uncertain significance rs1085307084 GRCh37 Chromosome 8, 17823587: 17823587
7 PCM1 NM_006197.3(PCM1): c.2935C> T (p.Gln979Ter) single nucleotide variant Uncertain significance rs1085307084 GRCh38 Chromosome 8, 17966078: 17966078

Cosmic variations for Thyroid Cancer, Nonmedullary, 1:

9
(show top 50) (show all 293)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6961574 ZFHX3 thyroid,NS,carcinoma,papillary carcinoma c.5539C>T p.Q1847* 16:72797143-72797143 55
2 COSM6954354 VTCN1 thyroid,NS,carcinoma,papillary carcinoma c.399C>G p.I133M 1:117156620-117156620 55
3 COSM17721 VHL thyroid,NS,carcinoma,papillary carcinoma c.241C>T p.P81S 3:10142088-10142088 55
4 COSM26416 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1867G>T p.A623S 14:81143925-81143925 55
5 COSM26449 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1358T>C p.M453T 14:81143416-81143416 55
6 COSM6918838 TSC2 thyroid,NS,carcinoma,papillary carcinoma c.4468G>C p.E1490Q 16:2084690-2084690 55
7 COSM10704 TP53 thyroid,NS,carcinoma,papillary carcinoma c.844C>T p.R282W 17:7673776-7673776 55
8 COSM10739 TP53 thyroid,NS,carcinoma,papillary carcinoma c.481G>A p.A161T 17:7675131-7675131 55
9 COSM43980 TP53 thyroid,NS,carcinoma,papillary carcinoma c.691A>G p.T231A 17:7674272-7674272 55
10 COSM10863 TP53 thyroid,NS,carcinoma,papillary carcinoma c.833C>T p.P278L 17:7673787-7673787 55
11 COSM44988 TP53 thyroid,NS,carcinoma,papillary carcinoma c.374C>T p.T125M 17:7675995-7675995 55
12 COSM10771 TP53 thyroid,NS,carcinoma,papillary carcinoma c.749C>T p.P250L 17:7674214-7674214 55
13 COSM10659 TP53 thyroid,NS,carcinoma,papillary carcinoma c.817C>T p.R273C 17:7673803-7673803 55
14 COSM10834 TP53 thyroid,NS,carcinoma,papillary carcinoma c.711G>A p.M237I 17:7674252-7674252 55
15 COSM10867 TP53 thyroid,NS,carcinoma,papillary carcinoma c.797G>A p.G266E 17:7673823-7673823 55
16 COSM44225 TP53 thyroid,NS,carcinoma,papillary carcinoma c.859G>A p.E287K 17:7673761-7673761 55
17 COSM6959677 SYK thyroid,NS,carcinoma,papillary carcinoma c.65G>A p.R22Q 9:90843963-90843963 55
18 COSM6974249 SPEN thyroid,NS,carcinoma,papillary carcinoma c.10348C>T p.Q3450* 1:15937484-15937484 55
19 COSM14195 SMAD4 thyroid,NS,carcinoma,papillary carcinoma c.1482C>T p.D494D 18:51078290-51078290 55
20 COSM14186 SMAD4 thyroid,NS,carcinoma,papillary carcinoma c.788A>G p.N263S 18:51058340-51058340 55
21 COSM14163 SMAD4 thyroid,NS,carcinoma,papillary carcinoma c.931C>T p.Q311* 18:51059892-51059892 55
22 COSM14185 SMAD4 thyroid,NS,carcinoma,papillary carcinoma c.676G>A p.A226T 18:51058133-51058133 55
23 COSM14189 SMAD4 thyroid,NS,carcinoma,papillary carcinoma c.971G>A p.C324Y 18:51065438-51065438 55
24 COSM14196 SMAD4 thyroid,NS,carcinoma,papillary carcinoma c.1648C>T p.P550S 18:51078456-51078456 55
25 COSM14193 SMAD4 thyroid,NS,carcinoma,papillary carcinoma c.1487G>A p.R496H 18:51078295-51078295 55
26 COSM3407453 SF3B1 thyroid,NS,carcinoma,papillary carcinoma c.1781G>A p.R594Q 2:197402974-197402974 55
27 COSM6954357 SETD2 thyroid,NS,carcinoma,papillary carcinoma c.3247C>G p.H1083D 3:47106080-47106080 55
28 COSM6945083 RICTOR thyroid,NS,carcinoma,papillary carcinoma c.2539C>T p.L847F 5:38955665-38955665 55
29 COSM3390655 RBM10 thyroid,NS,carcinoma,papillary carcinoma c.2548C>T p.Q850* 23:47186268-47186268 55
30 COSM6981514 RBM10 thyroid,NS,carcinoma,papillary carcinoma c.853C>T p.Q285* 23:47179447-47179447 55
31 COSM6944613 RBM10 thyroid,NS,carcinoma,papillary carcinoma c.1573C>T p.Q525* 23:47181644-47181644 55
32 COSM6917469 RAD51B thyroid,NS,carcinoma,papillary carcinoma c.940G>C p.D314H 14:68411510-68411510 55
33 COSM6944180 RAD50 thyroid,NS,carcinoma,papillary carcinoma c.3057A>T p.Q1019H 5:132637199-132637199 55
34 COSM6923704 PTPRT thyroid,NS,carcinoma,papillary carcinoma c.3655G>T p.G1219W 20:42102249-42102249 55
35 COSM6961568 PTPRD thyroid,NS,carcinoma,papillary carcinoma c.1616C>G p.P539R 9:8507362-8507362 55
36 COSM13015 PTPN11 thyroid,NS,carcinoma,papillary carcinoma c.215C>T p.A72V 12:112450395-112450395 55
37 COSM5092 PTEN thyroid,NS,carcinoma,papillary carcinoma c.385G>A p.G129R 10:87933144-87933144 55
38 COSM5064 PTEN thyroid,NS,carcinoma,papillary carcinoma c.44G>A p.R15K 10:87864513-87864513 55
39 COSM4016454 PTEN thyroid,NS,carcinoma,papillary carcinoma c.295G>A p.E99K 10:87933054-87933054 55
40 COSM5034 PTEN thyroid,NS,carcinoma,papillary carcinoma c.425G>A p.R142Q 10:87933184-87933184 55
41 COSM3394847 PMS2 thyroid,NS,carcinoma,papillary carcinoma c.206C>T p.S69L 7:6004016-6004016 55
42 COSM1666844 PIK3CA thyroid,NS,carcinoma,papillary carcinoma c.977C>T p.S326F 3:179203707-179203707 55
43 COSM775 PIK3CA thyroid,NS,carcinoma,papillary carcinoma c.3140A>G p.H1047R 3:179234297-179234297 55
44 COSM763 PIK3CA thyroid,NS,carcinoma,papillary carcinoma c.1633G>A p.E545K 3:179218303-179218303 55
45 COSM29106 PIK3CA thyroid,NS,carcinoma,papillary carcinoma c.1658G>A p.S553N 3:179218328-179218328 55
46 COSM29110 PIK3CA thyroid,NS,carcinoma,papillary carcinoma c.3115T>C p.F1039L 3:179234272-179234272 55
47 COSM33701 PIK3CA thyroid,NS,carcinoma,papillary carcinoma c.1589A>G p.Q530R 3:179218259-179218259 55
48 COSM776 PIK3CA thyroid,NS,carcinoma,papillary carcinoma c.3140A>T p.H1047L 3:179234297-179234297 55
49 COSM778 PIK3CA thyroid,NS,carcinoma,papillary carcinoma c.2102A>C p.H701P 3:179221072-179221072 55
50 COSM12597 PIK3CA thyroid,NS,carcinoma,papillary carcinoma c.3145G>C p.G1049R 3:179234302-179234302 55

Copy number variations for Thyroid Cancer, Nonmedullary, 1 from CNVD:

7 (show all 16)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13343 1 1 124300000 Chromosomal rearrang ement Papillary thyroid carcinoma
2 13804 1 1 60900000 Chromosomal rearrang ement Papillary thyroid carcinoma
3 19995 1 152394403 152431233 Translate TPM3 Papillary thyroid carcinoma
4 42899 10 42100000 53300000 Chromosomal rearrang ement Papillary thyroid carcinoma
5 44673 10 61218526 61336824 Translate D10S170 Papillary thyroid carcinoma
6 91970 15 37900000 47600000 Copy number FGF7 Papillary thyroid carcinoma
7 95418 15 76100000 86900000 Copy number AKAP13 Papillary thyroid carcinoma
8 96732 15 92330402 92376057 Translate GOLGA5 Papillary thyroid carcinoma
9 106730 17 1 11200000 Copy number TRE2 Papillary thyroid carcinoma
10 140387 2 197100000 209100000 Copy number TRAK2 Papillary thyroid carcinoma
11 148729 2 83700000 91000000 Amplification TB10 Papillary thyroid carcinoma
12 166063 3 1 14700000 Chromosomal rearrang ement Papillary thyroid carcinoma
13 166395 3 101910849 101950501 Translate TFG Papillary thyroid carcinoma
14 194280 5 139000000 143100000 Copy number EIF4EBP3 Papillary thyroid carcinoma
15 219438 7 126900000 158821424 Chromosomal rearrangement Papillary thyroid carcinoma
16 232143 8 112100000 146364022 Amplification Papillary thyroid cancer

Expression for Thyroid Cancer, Nonmedullary, 1

Search GEO for disease gene expression data for Thyroid Cancer, Nonmedullary, 1.

Pathways for Thyroid Cancer, Nonmedullary, 1

GO Terms for Thyroid Cancer, Nonmedullary, 1

Biological processes related to Thyroid Cancer, Nonmedullary, 1 according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.76 APELA BRAF MIR221 MIR222
2 positive regulation of G1/S transition of mitotic cell cycle GO:1900087 9.55 MIR221 MIR222
3 positive regulation of erythrocyte differentiation GO:0045648 9.54 MIR221 MIR222
4 endoderm development GO:0007492 9.52 APELA NKX2-1
5 thyroid gland development GO:0030878 9.51 BRAF NKX2-1
6 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.49 APELA MIR146A
7 negative regulation of cytokine production involved in inflammatory response GO:1900016 9.48 MIR221 MIR222
8 negative regulation by host of viral genome replication GO:0044828 9.43 MIR221 MIR222
9 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.4 MIR221 MIR222
10 negative regulation of cell adhesion molecule production GO:0060354 9.37 MIR221 MIR222
11 negative regulation of TRAIL-activated apoptotic signaling pathway GO:1903122 9.32 MIR221 MIR222
12 positive regulation of Schwann cell migration GO:1900149 9.26 MIR221 MIR222
13 negative regulation of hematopoietic stem cell proliferation GO:1902034 9.16 MIR221 MIR222
14 positive regulation of Schwann cell proliferation involved in axon regeneration GO:1905046 8.96 MIR221 MIR222
15 positive regulation of axon regeneration GO:0048680 8.8 BRAF MIR221 MIR222

Sources for Thyroid Cancer, Nonmedullary, 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....